1.
ErbB4 tyrosine kinase inhibition impairs neuromuscular development in zebrafish embryos. Paatero I, Veikkolainen V, Mäenpää M, Schmelzer E, Belting HG, Pelliniemi LJ, Elenius K. Mol Biol Cell. 2019 Jan 15;30(2):209-218. doi: 10.1091/mbc.E18-07-0460. Epub 2018 Nov 21.

2.
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin. Narvi E, Vaparanta K, Karrila A, Chakroborty D, Knuutila S, Pulliainen A, Sundvall M, Elenius K. Sci Rep. 2018 Nov 8;8(1):16579. doi: 10.1038/s41598-018-34938-y.

3.
Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target. Heliste J, Jokilammi A, Paatero I, Chakroborty D, Stark C, Savunen T, Laaksonen M, Elenius K. BMC Cardiovasc Disord. 2018 Oct 20;18(1):196. doi: 10.1186/s12872-018-0933-y.

4.
The Mutational Profile of Unicystic Ameloblastoma. Heikinheimo K, Huhtala JM, Thiel A, Kurppa KJ, Heikinheimo H, Kovac M, Kragelund C, Warfvinge G, Dawson H, Elenius K, Ristimäki A, Baumhoer D, Morgan PR. J Dent Res. 2019 Jan;98(1):54-60. doi: 10.1177/0022034518798810. Epub 2018 Sep 14.

5.
Gamma-secretase-dependent signaling of receptor tyrosine kinases. Merilahti JAM, Elenius K. Oncogene. 2019 Jan;38(2):151-163. doi: 10.1038/s41388-018-0465-z. Epub 2018 Aug 30. Review.

6.
SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase. Knittle AM, Helkkula M, Johnson MS, Sundvall M, Elenius K. J Biol Chem. 2017 Dec 1;292(48):19890-19904. doi: 10.1074/jbc.M117.794271. Epub 2017 Oct 3.

7.
Genome-wide screen of gamma-secretase-mediated intramembrane cleavage of receptor tyrosine kinases. Merilahti JAM, Ojala VK, Knittle AM, Pulliainen AT, Elenius K. Mol Biol Cell. 2017 Nov 1;28(22):3123-3131. doi: 10.1091/mbc.E17-04-0261. Epub 2017 Sep 13.

8.
Human Metaplastic Breast Carcinoma and Decorin. Boström P, Sainio A, Eigėlienė N, Jokilammi A, Elenius K, Koskivuo I, Järveläinen H. Cancer Microenviron. 2017 Dec;10(1-3):39-48. doi: 10.1007/s12307-017-0195-8. Epub 2017 Jun 26.

9.
Activating ERBB4 mutations in non-small cell lung cancer. Kurppa KJ, Denessiouk K, Johnson MS, Elenius K. Oncogene. 2016 Mar 10;35(10):1283-91. doi: 10.1038/onc.2015.185. Epub 2015 Jun 8.

10.
Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis. Wali VB, Gilmore-Hebert M, Mamillapalli R, Haskins JW, Kurppa KJ, Elenius K, Booth CJ, Stern DF. Breast Cancer Res. 2014 Dec 17;16(6):501. doi: 10.1186/s13058-014-0501-z.

11.
Novel targets for the treatment of ameloblastoma. Heikinheimo K, Kurppa KJ, Elenius K. J Dent Res. 2015 Feb;94(2):237-40. doi: 10.1177/0022034514560373. Epub 2014 Nov 25. Review. No abstract available.

12.
ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis. Naillat F, Veikkolainen V, Miinalainen I, Sipilä P, Poutanen M, Elenius K, Vainio SJ. Mol Endocrinol. 2014 Sep;28(9):1534-46. doi: 10.1210/me.2013-1244. Epub 2014 Jul 24.

13.
ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer. Kurppa KJ, Rokavec M, Sundvall M, Kellokumpu-Lehtinen PL, Joensuu H, Brauch H, Elenius K. PLoS One. 2014 Jul 18;9(7):e102388. doi: 10.1371/journal.pone.0102388. eCollection 2014.

14.
Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland. Paatero I, Seagroves TN, Vaparanta K, Han W, Jones FE, Johnson RS, Elenius K.J Biol Chem. 2014 Aug 8;289(32):22459-69. doi: 10.1074/jbc.M113.533497. Epub 2014 Jun 25.

15.
High frequency of BRAF V600E mutations in ameloblastoma. Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K.J Pathol. 2014 Apr;232(5):492-8. doi: 10.1002/path.4317. Epub 2014 Jan 31.

16.
ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, Belzil VV, Dion PA, Higasa K, Doi K, Ishiura H, Mitsui J, Date H, Ahsan B, Matsukawa T, Ichikawa Y, Moritoyo T, Ikoma M, Hashimoto T, Kimura F, Murayama S, Onodera O, Nishizawa M, Yoshida M, Atsuta N, Sobue G; JaCALS, Fifita JA, Williams KL, Blair IP, Nicholson GA, Gonzalez-Perez P, Brown RH Jr, Nomoto M, Elenius K, Rouleau GA, Fujiyama A, Morishita S, Goto J, Tsuji S. Am J Hum Genet. 2013 Nov 7;93(5):900-5. doi: 10.1016/j.ajhg.2013.09.008. Epub 2013 Oct 10.

17.
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Paatero I, Lassus H, Junttila TT, Kaskinen M, Bützow R, Elenius K.
Gynecol Oncol. 2013 Apr;129(1):179-87. doi: 10.1016/j.ygyno.2012.12.044. Epub 2013 Jan 9.

18.
Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. Nordberg J, Mpindi JP, Iljin K, Pulliainen AT, Kallajoki M, Kallioniemi O, Elenius K, Elenius V. PLoS One. 2012;7(12):e50819. doi: 10.1371/journal.pone.0050819. Epub 2012 Dec 5.

19.
Translation of a research-based genetic test on a rare syndrome into clinical service testing, with sotos syndrome as an example. Pohjola P, Peippo M, Penttinen MT, Elenius K, Kääriäinen H. Genet Test Mol Biomarkers. 2012 Oct;16(10):1188-94. doi: 10.1089/gtmb.2012.0153. Epub 2012 Aug 27.

20.
Proteolytic processing of ErbB4 in breast cancer. Hollmén M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K. PLoS One. 2012;7(6):e39413. doi: 10.1371/journal.pone.0039413. Epub 2012 Jun 22.

21.
Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. Sundvall M, Korhonen A, Vaparanta K, Anckar J, Halkilahti K, Salah Z, Aqeilan RI, Palvimo JJ, Sistonen L, Elenius K. J Biol Chem. 2012 Jun 29;287(27):23216-26. doi: 10.1074/jbc.M111.335927. Epub 2012 May 14.

22.
Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. Paatero I, Jokilammi A, Heikkinen PT, Iljin K, Kallioniemi OP, Jones FE, Jaakkola PM, Elenius K. J Biol Chem. 2012 Mar 23;287(13):9659-71. doi: 10.1074/jbc.M111.299537. Epub 2012 Feb 3.

23.
Interaction between marrow-derived human mesenchymal stem cells and peripheral blood mononuclear cells in endothelial cell differentiation. Joensuu K, Paatero I, Alm JJ, Elenius K, Aro HT, Heino TJ, Hentunen TA. Scand J Surg. 2011;100(3):216-22.

24.
ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. Veikkolainen V, Naillat F, Railo A, Chi L, Manninen A, Hohenstein P, Hastie N, Vainio S, Elenius K.J Am Soc Nephrol. 2012 Jan;23(1):112-22. doi: 10.1681/ASN.2011020160. Epub 2011 Nov 10.

25.
Function of ERBB4 is determined by alternative splicing. Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K. Cell Cycle. 2011 Aug 15;10(16):2647-57. Epub 2011 Aug 15. Review.

26.
Cell death or survival promoted by alternative isoforms of ErbB4. Sundvall M, Veikkolainen V, Kurppa K, Salah Z, Tvorogov D, van Zoelen EJ, Aqeilan R, Elenius K. Mol Biol Cell. 2010 Dec;21(23):4275-86. doi: 10.1091/mbc.E10-04-0332. Epub 2010 Oct 13.

27.
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Sundvall M, Karrila A, Nordberg J, Grénman R, Elenius K. Expert Opin Emerg Drugs. 2010 Jun;15(2):185-201. doi: 10.1517/14728211003716442. Review.

28.
Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2 induced anchorage-independent carcinoma cell growth. Jokilehto T, Högel H, Heikkinen P, Rantanen K, Elenius K, Sundström J, Jaakkola PM. Exp Cell Res. 2010 Apr 15;316(7):1169-78. doi: 10.1016/j.yexcr.2010.02.012. Epub 2010 Feb 12.

29.
Potential of ErbB4 antibodies for cancer therapy. Hollmén M, Elenius K. Future Oncol. 2010 Jan;6(1):37-53. doi: 10.2217/fon.09.144. Review.

30.
Mutated ERBB4: a novel drug target in metastatic melanoma? Kurppa K, Elenius K. Pigment Cell Melanoma Res. 2009 Dec;22(6):708-10. doi: 10.1111/j.1755-148X.2009.00635.x. Epub 2009 Sep 7. No abstract available.

31.
ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA, Earp HS 3rd. Mol Cell Biol. 2009 Sep;29(18):4935-48. doi: 10.1128/MCB.01705-08. Epub 2009 Jul 13.

32.
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Iivanainen E, Lauttia S, Zhang N, Tvorogov D, Kulmala J, Grenman R, Salven P, Elenius K.
Microvasc Res. 2009 Dec;78(3):278-85. doi: 10.1016/j.mvr.2009.06.010. Epub 2009 Jul 9.

33.
Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, Grenman R, Jalkanen S. Neoplasia. 2009 Jul;11(7):629-36.

34.
ErbB targeted drugs and angiogenesis. Iivanainen E, Elenius K. Curr Vasc Pharmacol. 2010 May;8(3):421-31. Review.

35.
Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Zhang N, Erjala K, Kulmala J, Qiu X, Sundvall M, Elenius K, Grénman R. Radiother Oncol. 2009 Sep;92(3):388-92. doi: 10.1016/j.radonc.2009.04.019. Epub 2009 May 15.

36.
Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor. Määttä JA, Olli K, Henttinen T, Tuittila MT, Elenius K, Salmivirta M. BMC Cell Biol. 2009 Jan 26;10:5. doi: 10.1186/1471-2121-10-5.

37.
Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Hollmén M, Määttä JA, Bald L, Sliwkowski MX, Elenius K. Oncogene. 2009 Mar 12;28(10):1309-19. doi: 10.1038/onc.2008.481. Epub 2009 Jan 19.

38.
Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. Tvorogov D, Sundvall M, Kurppa K, Hollmén M, Repo S, Johnson MS, Elenius K. J Biol Chem. 2009 Feb 27;284(9):5582-91. doi: 10.1074/jbc.M805438200. Epub 2008 Dec 19.

39.
ErbB4 and its isoforms: patentable drug targets? Paatero I, Elenius K. Recent Pat DNA Gene Seq. 2008;2(1):27-33. Review.

40.
Role of ErbB4 in breast cancer. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K.J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):259-68. doi: 10.1007/s10911-008-9079-3. Epub 2008 May 3. Review.

41.
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, Aqeilan RI, Elenius K. Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4162-7. doi: 10.1073/pnas.0708333105. Epub 2008 Mar 11.

42.
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Erjala K, Zhang N, Sundvall M, Kulmala J, Elenius K, Grénman R. Radiother Oncol. 2007 Oct;85(1):138-45.

43.
Association of Wwox with ErbB4 in breast cancer. Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H, Croce CM, Elenius K. Cancer Res. 2007 Oct 1;67(19):9330-6.

44.
O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Borgenström M, Wärri A, Hiilesvuo K, Käkönen R, Käkönen S, Nissinen L, Pihlavisto M, Marjamäki A, Vlodavsky I, Naggi A, Torri G, Casu B, Veromaa T, Salmivirta M, Elenius K. Semin Thromb Hemost. 2007 Jul;33(5):547-56.

45.
Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Ihalainen S, Soliymani R, Iivanainen E, Mykkänen K, Sainio A, Pöyhönen M, Elenius K, Järveläinen H, Viitanen M, Kalimo H, Baumann M.
Mol Med. 2007 May-Jun;13(5-6):305-14.

46.
Intra- and extracellular signaling by endothelial neuregulin-1. Iivanainen E, Paatero I, Heikkinen SM, Junttila TT, Cao R, Klint P, Jaakkola PM, Cao Y, Elenius K. Exp Cell Res. 2007 Aug 1;313(13):2896-909. Epub 2007 Apr 18.

47.
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Sundvall M, Peri L, Määttä JA, Tvorogov D, Paatero I, Savisalo M, Silvennoinen O, Yarden Y, Elenius K. Oncogene. 2007 Oct 18;26(48):6905-14. Epub 2007 May 7.

48.
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Järvelä S, Helin H, Haapasalo J, Järvelä T, Junttila TT, Elenius K, Tanner M, Haapasalo H, Isola J. Neuropathol Appl Neurobiol. 2006 Aug;32(4):441-50. Erratum in: Neuropathol Appl Neurobiol. 2006 Oct;32(5):568. Järvellä, S [corrected to Järvelä, Sally]; Järvellä, T [corrected to Järvelä, Timo].

49.
Epidermaalisen kasvutekijän reseptorin estäjät syövän hoidossa. Elenius K. Duodecim. 2006;122(11):1331-8. Finnish. No abstract available.

50.
The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS 3rd. Mol Biol Cell. 2006 Sep;17(9):4118-29. Epub 2006 Jul 12.

51.
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

52.
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. Mol Biol Cell. 2006 Jan;17(1):67-79. Epub 2005 Oct 26.

53.
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mialon A, Sankinen M, Söderström H, Junttila TT, Holmström T, Koivusalo R, Papageorgiou AC, Johnson RS, Hietanen S, Elenius K, Westermarck J. Mol Cell Biol. 2005 Jun;25(12):5040-51.

54.
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K. Cancer Res. 2005 Feb 15;65(4):1384-93.

55.
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Ann Oncol. 2005 Feb;16(2):273-8.

56.
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Mol Cancer Ther. 2004 Dec;3(12):1585-92.

57.
ErbB4 is downregulated in renal cell carcinoma–a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Thomasson M, Hedman H, Junttila TT, Elenius K, Ljungberg B, Henriksson R. Acta Oncol. 2004;43(5):453-9.

58.
Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. Elenius V, Götte M, Reizes O, Elenius K, Bernfield M. J Biol Chem. 2004 Oct 1;279(40):41928-35. Epub 2004 Jun 25.

59.
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Junttila TT, Laato M, Vahlberg T, Söderström KO, Visakorpi T, Isola J, Elenius K. Clin Cancer Res. 2003 Nov 1;9(14):5346-57.

60.
Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, Sihombing L, Sundvall M, Maatta JA, Laine VJ, Yla-Herttuala S, Higashiyama S, Alitalo K, Elenius K.FASEB J. 2003 Sep;17(12):1609-21.